Navigating the Section 101 Landscape: REGENXBIO v. Sarepta and Its Implications for Patent Eligibility

In February 2026, the U.S. Court of Appeals for the Federal Circuit issued a precedential decision in REGENXBIO Inc. v. Sarepta Therapeutics, Inc., reversing a district court ruling that had invalidated a gene-therapy patent under 35 U.S.C. §101 (Section 101).... By: Ropes & Gray LLP